Ellen MBA - Werewolf Therapeutics Chief Officer
| HOWL Stock | USD 2.00 0.10 5.26% |
Insider
Ellen MBA is Chief Officer of Werewolf Therapeutics
| Age | 48 |
| Address | 200 Talcott Ave, Watertown, MA, United States, 02472 |
| Phone | 617 952 0555 |
| Web | https://werewolftx.com |
Werewolf Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2616) % which means that it has lost $0.2616 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6156) %, meaning that it created substantial loss on money invested by shareholders. Werewolf Therapeutics' management efficiency ratios could be used to measure how well Werewolf Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.22. The value of Return On Capital Employed is expected to slide to -0.27. At this time, Werewolf Therapeutics' Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 38.3 M this year, although the value of Other Assets will most likely fall to 0.95.Similar Executives
| Showing other executives | INSIDER Age | ||
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Bradley JD | Lumos Pharma | 45 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| David MBA | Seres Therapeutics | 63 | |
| Carl Langren | Lumos Pharma | 69 | |
| Lori CPA | Lumos Pharma | 40 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| BBA CPA | Lumos Pharma | 57 | |
| Lisa Miller | Lumos Pharma | N/A | |
| MD BA | Lumos Pharma | 69 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.26 |
Werewolf Therapeutics Leadership Team
Elected by the shareholders, the Werewolf Therapeutics' board of directors comprises two types of representatives: Werewolf Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Werewolf. The board's role is to monitor Werewolf Therapeutics' management team and ensure that shareholders' interests are well served. Werewolf Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Werewolf Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randi MD, Chief Officer | ||
| Timothy CPA, Treasurer CFO | ||
| Cynthia SeidelDugan, Chief Officer | ||
| Ellen MBA, Chief Officer | ||
| Daniel Hicklin, CEO, Founder | ||
| William Winston, Senior Research | ||
| Chulani Karunatilake, Chief Officer | ||
| Reid Leonard, Chief Officer |
Werewolf Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Werewolf Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (19.55) % | ||||
| Current Valuation | 3.08 M | ||||
| Shares Outstanding | 44.56 M | ||||
| Shares Owned By Insiders | 6.11 % | ||||
| Shares Owned By Institutions | 72.60 % | ||||
| Number Of Shares Shorted | 1.23 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.00 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.